273 related articles for article (PubMed ID: 33444194)
21. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
22. An EQ-5D-5L Value Set for Vietnam.
Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
[TBL] [Abstract][Full Text] [Related]
23. Measuring health-related quality of life in the general population and Roma communities in Romania: study protocol for two cross-sectional studies.
Olariu E; Paveliu MS; Baican E; Oluboyede Y; Vale L; Niculescu-Aron IG
BMJ Open; 2019 Aug; 9(8):e029067. PubMed ID: 31427330
[TBL] [Abstract][Full Text] [Related]
24. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
25. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life among Indian population: The EQ-5D population norms for India.
Jyani G; Prinja S; Garg B; Kaur M; Grover S; Sharma A; Goyal A
J Glob Health; 2023 Feb; 13():04018. PubMed ID: 36799239
[TBL] [Abstract][Full Text] [Related]
27. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
28. Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets.
Waudby-Smith I; Pickard AS; Xie F; Pullenayegum EM
Med Decis Making; 2020 May; 40(4):483-497. PubMed ID: 32517541
[No Abstract] [Full Text] [Related]
29. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
30. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
31. Valuation of the EQ-5D-5L in Taiwan.
Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
[TBL] [Abstract][Full Text] [Related]
32. Valuing health-related quality of life: An EQ-5D-5L value set for England.
Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
[TBL] [Abstract][Full Text] [Related]
33. A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets.
Rowen D; Mukuria C; McDool E
Pharmacoeconomics; 2022 Sep; 40(9):863-882. PubMed ID: 35829931
[TBL] [Abstract][Full Text] [Related]
34. The Indonesian EQ-5D-5L Value Set.
Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
[TBL] [Abstract][Full Text] [Related]
35. Protocol for estimating the willingness-to-pay-based value for a quality-adjusted life year to aid health technology assessment in India: a cross-sectional study.
Chugh Y; Jyani G; Trivedi M; Albert S; Kar SS; Patro B; Raman S; Rajsekar K; Baker RM; Donaldson C; Prinja S
BMJ Open; 2023 Feb; 13(2):e065591. PubMed ID: 36797026
[TBL] [Abstract][Full Text] [Related]
36. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
37. Valuing health-related quality of life using a hybrid approach: Tunisian value set for the EQ-5D-3L.
Chemli J; Drira C; Felfel H; Roudijk B; Al Sayah F; Kouki M; Kooli A; Razgallah Khrouf M
Qual Life Res; 2021 May; 30(5):1445-1455. PubMed ID: 33447958
[TBL] [Abstract][Full Text] [Related]
38. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
[TBL] [Abstract][Full Text] [Related]
39. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
40. Estimating an EQ-5D-5L Value Set for China.
Luo N; Liu G; Li M; Guan H; Jin X; Rand-Hendriksen K
Value Health; 2017 Apr; 20(4):662-669. PubMed ID: 28408009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
